Consequences of Total and Subtotal Myeloperoxidase Deficiency: Risk or Benefit ?

  title={Consequences of Total and Subtotal Myeloperoxidase Deficiency: Risk or Benefit ?},
  author={Dolphe Kutter and Paul Devaquet and G Vanderstocken and J. M. Paulus and V Marchal and André Gothot},
  journal={Acta Haematologica},
  pages={10 - 15}
A group of 100 totally or subtotally myeloperoxidase (MPO)-deficient individuals was compared to a reference population of 118 probands selected at random. Data for a protective effect of the deficiency against cardiovascular damage are presented. On the other hand, a significantly higher occurrence of severe infections and chronic inflammatory processes was noted among the deficient patients. An increased incidence of cancer among the MPO-deficient individuals was not demonstrated. 

Figures and Tables from this paper

Unexpected combination: DiGeorge syndrome and myeloperoxidase deficiency

A 3-year-old boy who presented with recurrent bacterial and fungal infections and a known diagnosis of partial DiGeorge (22q11.2 deletion) syndrome is reported, raising awareness of the possibility of two rare diseases occurring in a single patient.

Case report of myeloperoxidase deficiency associated with disseminated paracoccidioidomycosis and peritoneal tuberculosis.

A patient who had MOP deficiency, who presented with a subacute form of paracoccidioidomycosis and later with peritoneal tuberculosis, gives important evidence of an association between Mop deficiency and increased susceptibility to infection by ParacoccIDioides brasiliensis and Mycobacterium tuberculosis.

Rare germline alterations of myeloperoxidase predispose to myeloid neoplasms

This study for the first time demonstrates that germline MPO variants may constitute risk alleles for MN evolution and demonstrates that H2O2-induced DNA damage and activation of error-prone DNA repair may result in secondary genetic damage potentially predisposing to leukemia leukemic evolution.

Growing Significance of Myeloperoxidase in Non-infectious Diseases

A review of the broad range of diseases involving MPO points out the possible use of this protein as a new clinical marker and a future therapeutic target.

Is myeloperoxidase a useful marker to predict the risk of cardiovascular events?

The evidence supporting a role for MPO as a marker of plaque instability is described and the evidence for an association between MPO levels and the risk of future cardiovascular risk is discussed.

The use of myeloperoxidase as a risk marker for atherosclerosis

  • V. Nambi
  • Biology
    Current atherosclerosis reports
  • 2005
The oxidation products generated by MPO have been shown to be related to various stages of atheroma development and to be enriched in human atheromas and rupture-prone plaques.

Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes

The aim of the study was to compare MPO level across the entire spectrum of CAD, to assess the accuracy of MPO in predicting acute coronary syndromes and to define independent correlates ofMPO level.

Myeloperoxidase: A mechanistically linked biomarker for cardiovascular disease

This review focuses on recent literature and background relevant to examining the role and potential clinical use of myeloperoxidase in cardiovascular disease.



Does a relationship exist between neutrophil myeloperoxidase deficiency and the occurrence of neoplasms?

It is found that the enzyme defect is associated with a marked impairment in the killing of both S. aureus and C. albicans, without affecting microbicidal activity against S. faecalis.

Hereditary myeloperoxidase deficiency: study of 12 cases.

12 cases of hereditary myeloperoxidase (MPO) deficiency are reported and MPO deficiency was found to follow autosomal recessive inheritance and only rarely to have clinical effects.

Hereditary myeloperoxidase deficiency.

Leukocytes from a subject with complete MPO deficiency and from some subjects with partial deficiency have impaired bactericidal activity against S. aureus, supporting the concept of multiple leukocyte bacterial killing systems.

Myeloperoxidase deficiency: prevalence and clinical significance.

Although MPO appears to be necessary for killing of Candida species by neutrophils, the importance of its role in normal antibacterial defense must be re-evaluated.

Polymorphonuclear leukocyte myeloperoxidase deficiency in a patient with myelomonocytic leukemia.

In the following case myelomonocytic leukemia was associated with markedly deficient myeloperoxidase and abnormal neutrophil bactericidal function.

Characterization of hereditary partial myeloperoxidase deficiency.

The data suggest either that the parents are heterozygous and the sons homozygous for hereditary partial myeloperoxidase deficiency or that each parent is heterozygously for a different type of myelopersporine deficiency and the Sons combine both deficiencies.

Evidence for a pretranslational defect in hereditary and acquired myeloperoxidase deficiency.

The results suggest that a pretranslational defect is one mechanism leading to MPO deficiency, and isolated an intron specific probe for MPO and used it and a cDNA probe to study further the molecular basis of this defect.

Biochemical and immunologic analysis of hereditary myeloperoxidase deficiency.

It is concluded that partial MPO deficiency is characterized by the presence of electrophoretically and immunologically normal MPO in amounts approximately one-half that seen in PMN from normal subjects.

Leukocyte myeloperoxidase deficiency and disseminated candidiasis: the role of myeloperoxidase in resistance to Candida infection.

The findings suggest that hereditary MPO deficiency is transmitted as an autosomal recessive characteristic, that the homozygous state conveys enhanced susceptibility to disseminated candidiasis, and that MPO is necessary for candidacidal activity in human neutrophils.